94 related articles for article (PubMed ID: 10346882)
21. Usage of radiopharmaceuticals in the development of pharmaceutical drug delivery systems: validation of [99mTc]DTPA and [99mTc]ECD.
Terán M; Savio E; Paolino A; Frier M
Eur J Pharm Biopharm; 2004 Mar; 57(2):347-52. PubMed ID: 15018995
[TBL] [Abstract][Full Text] [Related]
22. Fatty acid oxidation is decreased in the liver of ovariectomized rats.
Paquette A; Chapados NA; Bergeron R; Lavoie JM
Horm Metab Res; 2009 Jul; 41(7):511-5. PubMed ID: 19241328
[TBL] [Abstract][Full Text] [Related]
23. Differences in the intracellular processing of the radiolabel following the uptake of iodine-125- and technetium-99m-neogalactosyl albumin by the isolated perfused rat liver.
Gore S; Morris AI; Gilmore IT; Maltby PJ; Thornback JR; Billington D
J Nucl Med; 1991 Mar; 32(3):506-11. PubMed ID: 2005461
[TBL] [Abstract][Full Text] [Related]
24. Modulation of the hepatic malonyl-CoA-carnitine palmitoyltransferase 1A partnership creates a metabolic switch allowing oxidation of de novo fatty acids.
Akkaoui M; Cohen I; Esnous C; Lenoir V; Sournac M; Girard J; Prip-Buus C
Biochem J; 2009 May; 420(3):429-38. PubMed ID: 19302064
[TBL] [Abstract][Full Text] [Related]
25. A moderate increase in carnitine palmitoyltransferase 1a activity is sufficient to substantially reduce hepatic triglyceride levels.
Stefanovic-Racic M; Perdomo G; Mantell BS; Sipula IJ; Brown NF; O'Doherty RM
Am J Physiol Endocrinol Metab; 2008 May; 294(5):E969-77. PubMed ID: 18349115
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetic analysis of 123I-labeled medium chain fatty acid as a radiopharmaceutical for hepatic function based on beta-oxidation.
Yamamura N; Magata Y; Yamashita F; Hashida M; Saji H
Ann Nucl Med; 1999 Aug; 13(4):235-9. PubMed ID: 10510879
[TBL] [Abstract][Full Text] [Related]
27. High concentrations of stavudine impair fatty acid oxidation without depleting mitochondrial DNA in cultured rat hepatocytes.
Igoudjil A; Massart J; Begriche K; Descatoire V; Robin MA; Fromenty B
Toxicol In Vitro; 2008 Jun; 22(4):887-98. PubMed ID: 18299183
[TBL] [Abstract][Full Text] [Related]
28. Hepatic technetium Tc 99m-labeled sestamibi elimination rate and ABCB1 (MDR1) genotype as indicators of ABCB1 (P-glycoprotein) activity in patients with cancer.
Wong M; Evans S; Rivory LP; Hoskins JM; Mann GJ; Farlow D; Clarke CL; Balleine RL; Gurney H
Clin Pharmacol Ther; 2005 Jan; 77(1):33-42. PubMed ID: 15637529
[TBL] [Abstract][Full Text] [Related]
29. Down-regulation in muscle and liver lipogenic genes: EPA ethyl ester treatment in lean and overweight (high-fat-fed) rats.
Pérez-Echarri N; Pérez-Matute P; Marcos-Gómez B; Marti A; Martínez JA; Moreno-Aliaga MJ
J Nutr Biochem; 2009 Sep; 20(9):705-14. PubMed ID: 18829285
[TBL] [Abstract][Full Text] [Related]
30. In vivo oxidation of [9-14C] cyclic fatty acids derived from linolenic acid in the rat.
Bretillon L; Loreau O; Sébédio JL; Taran F
Reprod Nutr Dev; 2006; 46(2):189-93. PubMed ID: 16597424
[TBL] [Abstract][Full Text] [Related]
31. Dietary sesamin and docosahexaenoic and eicosapentaenoic acids synergistically increase the gene expression of enzymes involved in hepatic peroxisomal fatty acid oxidation in rats.
Arachchige PG; Takahashi Y; Ide T
Metabolism; 2006 Mar; 55(3):381-90. PubMed ID: 16483883
[TBL] [Abstract][Full Text] [Related]
32. Extension of the single amino acid chelate concept (SAAC) to bifunctional biotin analogues for complexation of the M(CO)3(+1) Core (M = Tc and Re): syntheses, characterization, biotinidase stability, and avidin binding.
James S; Maresca KP; Allis DG; Valliant JF; Eckelman W; Babich JW; Zubieta J
Bioconjug Chem; 2006; 17(3):579-89. PubMed ID: 16704194
[TBL] [Abstract][Full Text] [Related]
33. Ethanol consumption impairs regulation of fatty acid metabolism by decreasing the activity of AMP-activated protein kinase in rat liver.
García-Villafranca J; Guillén A; Castro J
Biochimie; 2008 Mar; 90(3):460-6. PubMed ID: 17997005
[TBL] [Abstract][Full Text] [Related]
34. Evaluation of radioiodinated medium chain fatty acids as new diagnostic agents for the determination of hepatic viability.
Yamamura N; Magata Y; Konishi J; Saji H
Eur J Nucl Med; 1999 Dec; 26(12):1597-605. PubMed ID: 10638412
[TBL] [Abstract][Full Text] [Related]
35. [Use of photoactivation in the preparation of radiopharmaceuticals. II. Dialysate of human leukocytes labelled with technetium (99mTc)].
Kleisner I; Komárek P; Konopková M; Komárková I
Ceska Slov Farm; 1997 Aug; 46(4):169-73. PubMed ID: 9377062
[TBL] [Abstract][Full Text] [Related]
36. Microautoradiographic study of technetium-99m colloid uptake by the rat liver.
Hindie E; Colas-Linhart N; Petiet A; Bok B
J Nucl Med; 1988 Jun; 29(6):1118-21. PubMed ID: 3373320
[TBL] [Abstract][Full Text] [Related]
37. [Use of photoactivation in the preparation of radiopharmaceuticals. I. Human immunoglobulin labelled with technetium (99mTc)].
Komárek P; Kleisner I; Konopková M; Komárko I
Ceska Slov Farm; 1997 Jun; 46(3):122-7. PubMed ID: 9440949
[TBL] [Abstract][Full Text] [Related]
38. Chemistry of technetium radiopharmaceuticals. I. Exploration of the tissue distribution and oxidation state consequences of technetium (IV) in Tc-Sn-gluconate and Tc-Sn-EHDP using carrier 99Tc.
Hambright P; McRae J; Valk PE; Bearden AJ; Shipley BA
J Nucl Med; 1975 Jun; 16(6):478-82. PubMed ID: 808594
[TBL] [Abstract][Full Text] [Related]
39. Progestin radiopharmaceuticals labeled with technetium and rhenium: synthesis, binding affinity, and in vivo distribution of a new progestin N2S2-metal conjugate.
O'Neil JP; Carlson KE; Anderson CJ; Welch MJ; Katzenellenbogen JA
Bioconjug Chem; 1994; 5(3):182-93. PubMed ID: 7918738
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of 99mtechnetium-radiopharmaceutical binding to blood elements using different trichloroacetic acid concentrations.
Freitas RS; Gutfilen B; da Fonseca LM; Bernardo-Filho M
Yale J Biol Med; 1996; 69(6):483-8. PubMed ID: 9436291
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
